Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2013

View Archived Issues

AnaptysBio adds new combination therapies to its immunotherapy portfolio

Galera initiates phase I head and neck cancer trial with new product

Pilocarpine/tolterodine fixed-dose combination is well tolerated at increased total daily doses

Researchers at Allergan disclose novel FPR2/ALX receptor ligands

Millennium Pharmaceuticals prepares new ubiquitin-activating enzyme inhibitors

Fedovapagon tested as potential therapy for nocturia associated with BPH

Teva Pharmaceutical begins phase I CEP-37440 study

Research Triangle Institute discloses novel CB1 receptor antagonists

Meda to acquire Acton Pharmaceuticals

Arizona State University synthesizes new agents for mitochondrial disorders

Researchers at IGM Biosciences patent novel antigen binding proteins

Ophthotech opens enrollment for phase III Fovista program

Subcutaneous Herceptin approved in Europe

Teva will not proceed with Nuvigil regulatory filing in depression following trial results

Debiopharm initiates phase I Debio-1347 trial

Aubagio approved in Europe for relapsing-remitting MS

RaQualia-Interprotein collaboration yields protein-protein interaction inhibitor hits

SBI Pharmaceuticals plans phase II study for chemotherapy-induced anemia

AZD-7507 demonstrates good oral pharmacokinetic profile in vivo

AesRx cleared to begin phase II trial of AES-103 in sickle cell disease

Antihypertensive, cardioprotective activity of intestinal NHE-3 blockade with SAR-218034

The University of Tsukuba presents novel agents for cancer

UCB Canada announces launch of rotigotine patch for patients with Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...